Together, these results suggest that targeting TREX1 is a promising strategy to induce a tumor-intrinsic innate immune response in drug-resistant SCLC by derepressing dsDNA-cGAS-STING pathway activation. The gene discussed is STING1; the disease is small cell lung carcinoma.